Developer docs
API playgroundTry for free, no card

Search company profiles

pHion Therapeutics Ltd.

Full company profile

uuid000a1ex

Namestring
pHion Therapeutics Ltd.
Websiteurl
phiontx.co.uk
Company typeenum
Private
Founded yearint
2017
Descriptiontext

pHion Therapeutics Ltd. is a UK-based, privately held clinical-stage biotechnology company founded in 2017 and headquartered in Belfast, focused on developing next-generation mRNA vaccines. The company's core asset is its proprietary RALA delivery platform, designed to improve the delivery efficiency and stability of mRNA vaccines relative to conventional lipid-based delivery systems. RALA underpins the company's pipeline, which targets both oncology and infectious disease indications. The lead candidate, PTX_V1, is advancing into clinical trials in 2024.

The company's go-to-market motion is partnership- and licensing-driven, typical of a clinical-stage biotech: pHion develops the technology and pipeline internally, then seeks co-development partnerships, licensing agreements, and royalty arrangements with larger pharmaceutical companies, with eventual product sales following regulatory approval. Revenue model types include licensing and royalties. The company is pre-revenue and has no publicly disclosed customers or commercial products at this stage.

Capital has come from a narrow investor base, including QUBIS in January 2020 and a second investment tranche from invoX Pharma Limited in June 2023, the latter specifically funding clinical development of PTX_V1 and expansion of the RALA platform. Leadership is anchored by founder and CEO Helen McCarthy and Chief Operating Officer Darach Neeson. Operating geographies are concentrated in the United Kingdom. Note: the company's listed website domain (phiontx.co.uk) currently displays third-party casino affiliate content unrelated to pHion's biotech operations, which warrants verification of the company's actual web presence.

Short descriptiontext

pHion Therapeutics Ltd. is a UK-based, privately held clinical-stage biotech developing next-generation mRNA vaccines using its proprietary RALA delivery platform for oncology and infectious disease indications, with lead candidate PTX_V1 advancing into clinical trials in 2024.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBelfast, United Kingdom
HQ citystring
Belfast
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
mRNA vaccine development, drug delivery platform, targeted nanoparticles, cancer immunotherapy, infectious disease vaccines
Industry2 codes
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Vaccine Development and Licensing
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biotech developing mRNA vaccines for oncology and infectious diseases. Revenue will likely come from licensing agreements, co-development partnerships, and eventual product sales following regulatory approval.

biospace.com
Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

pHion Therapeutics Ltd. is a clinical-stage biotechnology company developing next-generation mRNA vaccines using its proprietary RALA delivery platform. The company focuses on improving the efficiency and stability of mRNA vaccines for oncology and infectious disease indications, with lead candidate PTX_V1 advancing into clinical trials in 2024. Revenue is anticipated through licensing agreements, co-development partnerships, and eventual product sales following regulatory approval.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

pHion Therapeutics Ltd. is a UK-based company developing next-generation mRNA vaccines. The company's core technology consists of the proprietary RALA platform for mRNA vaccine delivery, which improves delivery efficiency and stability. The lead product candidate is PTX_V1, which is advancing into clinical trials in 2024 as part of a clinical pipeline focused on oncology and infectious disease vaccines.

Product and service1 record
1PTX_V1
CategoryTherapeutic vaccine candidate
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global leader in mRNA therapeutics and the dominant commercial mRNA vaccine player via Comirnaty. Directly comparable as an mRNA platform developer pursuing oncology and infectious-disease indications, but operates at vastly larger scale with validated products, capital, and clinical infrastructure that dwarf pHion's pre-clinical-stage RALA platform.

TypeBroad incumbent
Description

Major mRNA therapeutics company with Spikevax and an extensive pipeline spanning oncology vaccines (e.g., mRNA-4157) and infectious diseases. Highly comparable to pHion in target indications (oncology + infectious disease), but operates as the publicly-listed incumbent defining the mRNA delivery benchmark pHion's RALA platform would need to beat.

TypeDirect peer
Description

German mRNA therapeutics company developing optimized mRNA constructs and proprietary delivery approaches for oncology and prophylactic vaccines. Closely comparable in stage and business model - pre-commercial mRNA platform targeting similar indications - making it one of the most relevant benchmark peers for pHion's RALA technology.

TypeDirect peer
Description

Clinical-stage mRNA medicines company with a proprietary lipid-mediated delivery platform (LUNAR) and pipeline spanning infectious disease and oncology vaccines. Structurally analogous to pHion: delivery-platform differentiation, dual indication strategy, and licensing/partnering revenue model with large pharma.

5Translate Bio (Sanofi)
TypeDirect peer
Description

Pre-acquisition developer of an mRNA delivery platform (LUNAR-like lipid nanoparticles) targeting infectious disease and rare diseases; acquired by Sanofi in 2021 for ~$3.2B. Provides a useful comp on how Big Pharma values differentiated mRNA delivery platforms - the exit path pHion could pursue with invoX or other strategics.

TypeEmerging player
Description

Belgian clinical-stage biotech developing mRNA-based immunotherapies with proprietary delivery and immune-stimulation technology for oncology and infectious diseases. Closely comparable peer in geography, stage, and therapeutic focus, offering a useful benchmark on European mRNA vaccine platform deal terms and clinical trajectories.

7Ethris
TypeEmerging player
Description

Germany-based biotech developing SNIM® RNA-based therapeutics with proprietary stabilization and pulmonary delivery technology. Relevant peer in the stable, non-LNP RNA delivery space where pHion's RALA also competes, addressing similar respiratory and protein-replacement indications.

TypeEmerging player
Description

European clinical-stage biotech developing self-amplifying RNA (saRNA) vaccines and proprietary delivery technology for infectious disease and rare diseases. Comparable as a small, platform-driven mRNA vaccine company pursuing licensing partnerships with larger pharma.

TypeBroad incumbent
Description

Global vaccine incumbent that routinely licenses or in-licenses novel vaccine technologies and adjuvant/delivery platforms. Relevant potential strategic acquirer/partner for pHion's RALA-based oncology and infectious-disease vaccines, comparable to invoX's role today.

TypeBroad incumbent
Description

Major vaccine franchise with active mRNA strategy (including the Translate Bio acquisition and its own mRNA programs). Represents the type of strategic partner likely to evaluate RALA for in-licensing and serves as a benchmark acquirer profile similar to invoX.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

pHion Therapeutics Ltd.

Biopharmaceuticalsphiontx.co.uk

pHion Therapeutics Ltd. is a UK-based, privately held clinical-stage biotech developing next-generation mRNA vaccines using its proprietary RALA delivery platform for oncology and infectious disease indications, with lead candidate PTX_V1 advancing into clinical trials in 2024.

What pHion Therapeutics Ltd. does

pHion Therapeutics Ltd. is a UK-based, privately held clinical-stage biotechnology company founded in 2017 and headquartered in Belfast, focused on developing next-generation mRNA vaccines. The company's core asset is its proprietary RALA delivery platform, designed to improve the delivery efficiency and stability of mRNA vaccines relative to conventional lipid-based delivery systems. RALA underpins the company's pipeline, which targets both oncology and infectious disease indications. The lead candidate, PTX_V1, is advancing into clinical trials in 2024.

The company's go-to-market motion is partnership- and licensing-driven, typical of a clinical-stage biotech: pHion develops the technology and pipeline internally, then seeks co-development partnerships, licensing agreements, and royalty arrangements with larger pharmaceutical companies, with eventual product sales following regulatory approval. Revenue model types include licensing and royalties. The company is pre-revenue and has no publicly disclosed customers or commercial products at this stage.

Capital has come from a narrow investor base, including QUBIS in January 2020 and a second investment tranche from invoX Pharma Limited in June 2023, the latter specifically funding clinical development of PTX_V1 and expansion of the RALA platform. Leadership is anchored by founder and CEO Helen McCarthy and Chief Operating Officer Darach Neeson. Operating geographies are concentrated in the United Kingdom. Note: the company's listed website domain (phiontx.co.uk) currently displays third-party casino affiliate content unrelated to pHion's biotech operations, which warrants verification of the company's actual web presence.

pHion Therapeutics Ltd. firmographics

Firmographics
Name
pHion Therapeutics Ltd.
Website
https://phiontx.co.uk
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
pHion Therapeutics Ltd. is a UK-based, privately held clinical-stage biotech developing next-generation mRNA vaccines using its proprietary RALA delivery platform for oncology and infectious disease indications, with lead candidate PTX_V1 advancing into clinical trials in 2024.
Ownership category
akta.pro rank

pHion Therapeutics Ltd. industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • MRNA vaccine development
  • Drug delivery platform
  • Targeted nanoparticles
  • Cancer immunotherapy
  • Infectious disease vaccines

Where pHion Therapeutics Ltd. is headquartered

Location

Headquarters

HQ city
Belfast
HQ country
United Kingdom
HQ region
Europe

Markets served

pHion Therapeutics Ltd. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Vaccine Development and Licensing: Pre-revenue clinical-stage biotech developing mRNA vaccines for oncology and infectious diseases. Revenue will likely come from licensing agreements, co-development partnerships, and eventual product sales following regulatory approval.

Go-to-market motion1 record

pHion Therapeutics Ltd. product offering

Product offering

Core offering

pHion Therapeutics Ltd. is a clinical-stage biotechnology company developing next-generation mRNA vaccines using its proprietary RALA delivery platform. The company focuses on improving the efficiency and stability of mRNA vaccines for oncology and infectious disease indications, with lead candidate PTX_V1 advancing into clinical trials in 2024. Revenue is anticipated through licensing agreements, co-development partnerships, and eventual product sales following regulatory approval.

Product overview

pHion Therapeutics Ltd. is a UK-based company developing next-generation mRNA vaccines. The company's core technology consists of the proprietary RALA platform for mRNA vaccine delivery, which improves delivery efficiency and stability. The lead product candidate is PTX_V1, which is advancing into clinical trials in 2024 as part of a clinical pipeline focused on oncology and infectious disease vaccines.

Differentiator

Problem solved

Functional benefit

Products and services

  • PTX_V1

Companies that use pHion Therapeutics Ltd.

Customer profile

Segments1 record

Ideal customer profiles1 record

pHion Therapeutics Ltd. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

pHion Therapeutics Ltd. partnerships and signals

Strategic signal

Scale indicators1 record

Recent moves3 records

Expansion highlights4 records

pHion Therapeutics Ltd. competitors and assessment

Company assessment

Broad incumbents

  • BioNTech: Global leader in mRNA therapeutics and the dominant commercial mRNA vaccine player via Comirnaty. Directly comparable as an mRNA platform developer pursuing oncology and infectious-disease indications, but operates at vastly larger scale with validated products, capital, and clinical infrastructure that dwarf pHion's pre-clinical-stage RALA platform.
  • Moderna: Major mRNA therapeutics company with Spikevax and an extensive pipeline spanning oncology vaccines (e.g., mRNA-4157) and infectious diseases. Highly comparable to pHion in target indications (oncology + infectious disease), but operates as the publicly-listed incumbent defining the mRNA delivery benchmark pHion's RALA platform would need to beat.
  • GlaxoSmithKline (GSK) Vaccines: Global vaccine incumbent that routinely licenses or in-licenses novel vaccine technologies and adjuvant/delivery platforms. Relevant potential strategic acquirer/partner for pHion's RALA-based oncology and infectious-disease vaccines, comparable to invoX's role today.
  • Sanofi Vaccines: Major vaccine franchise with active mRNA strategy (including the Translate Bio acquisition and its own mRNA programs). Represents the type of strategic partner likely to evaluate RALA for in-licensing and serves as a benchmark acquirer profile similar to invoX.

Direct peers

  • CureVac: German mRNA therapeutics company developing optimized mRNA constructs and proprietary delivery approaches for oncology and prophylactic vaccines. Closely comparable in stage and business model - pre-commercial mRNA platform targeting similar indications - making it one of the most relevant benchmark peers for pHion's RALA technology.
  • Arcturus Therapeutics: Clinical-stage mRNA medicines company with a proprietary lipid-mediated delivery platform (LUNAR) and pipeline spanning infectious disease and oncology vaccines. Structurally analogous to pHion: delivery-platform differentiation, dual indication strategy, and licensing/partnering revenue model with large pharma.
  • Translate Bio (Sanofi): Pre-acquisition developer of an mRNA delivery platform (LUNAR-like lipid nanoparticles) targeting infectious disease and rare diseases; acquired by Sanofi in 2021 for ~$3.2B. Provides a useful comp on how Big Pharma values differentiated mRNA delivery platforms - the exit path pHion could pursue with invoX or other strategics.

Emerging players

  • eTheRNA immunotherapies: Belgian clinical-stage biotech developing mRNA-based immunotherapies with proprietary delivery and immune-stimulation technology for oncology and infectious diseases. Closely comparable peer in geography, stage, and therapeutic focus, offering a useful benchmark on European mRNA vaccine platform deal terms and clinical trajectories.
  • Ethris: Germany-based biotech developing SNIM® RNA-based therapeutics with proprietary stabilization and pulmonary delivery technology. Relevant peer in the stable, non-LNP RNA delivery space where pHion's RALA also competes, addressing similar respiratory and protein-replacement indications.
  • Ziphius Vaccines: European clinical-stage biotech developing self-amplifying RNA (saRNA) vaccines and proprietary delivery technology for infectious disease and rare diseases. Comparable as a small, platform-driven mRNA vaccine company pursuing licensing partnerships with larger pharma.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

pHion Therapeutics Ltd. social profiles

Digital presence

pHion Therapeutics Ltd. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

pHion Therapeutics Ltd. leadership team

Management profile

Number of profiles

Profiles2 records

pHion Therapeutics Ltd. funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

pHion Therapeutics Ltd. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about pHion Therapeutics Ltd.

What does pHion Therapeutics Ltd. do?

pHion Therapeutics Ltd. is a clinical-stage biotechnology company developing next-generation mRNA vaccines using its proprietary RALA delivery platform. The company focuses on improving the efficiency and stability of mRNA vaccines for oncology and infectious disease indications, with lead candidate PTX_V1 advancing into clinical trials in 2024. Revenue is anticipated through licensing agreements, co-development partnerships, and eventual product sales following regulatory approval.

Is pHion Therapeutics Ltd. a public or private company?

pHion Therapeutics Ltd. is a private company. It is classified as venture growth investor backed and is currently operating.

When was pHion Therapeutics Ltd. founded?

pHion Therapeutics Ltd. was founded in 2017. It employs 1 to 10 people.

Where is pHion Therapeutics Ltd. based?

pHion Therapeutics Ltd. is headquartered in Belfast, United Kingdom, in the Europe region.

How does pHion Therapeutics Ltd. make money?

One revenue line is on record: vaccine Development and Licensing.

Who are pHion Therapeutics Ltd.'s main competitors?

Broad incumbents on record are BioNTech, Moderna, GlaxoSmithKline (GSK) Vaccines and Sanofi Vaccines. Direct peers are CureVac, Arcturus Therapeutics and Translate Bio (Sanofi). Emerging players are eTheRNA immunotherapies, Ethris and Ziphius Vaccines.

Does pHion Therapeutics Ltd. have an API?

No public API is recorded for pHion Therapeutics Ltd..

What industry is pHion Therapeutics Ltd. in?

pHion Therapeutics Ltd.'s product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAA, mRNA Therapeutics (vaccines, protein replacement, immuno-oncology), with a secondary code of HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmiWeb.cominvoX Pharma Increases Investment in pHion Therapeutics to Further Develop Next Generation of mRNA VaccinesinvoX Pharma Limited has completed a second tranche of investment in pHion Therapeutics to advance its next-generation mRNA vaccines. This investment will support the advancement of pHion's lead therapeutic vaccine, PTX_V1, into clinical trials set to begin in the first half of 2024, addressing significant unmet clinical needs in HPV-related cancers. The investment has received all necessary regulatory approvals, demonstrating invoX's commitment to collaboration with regulators.BioSpaceinvoX Pharma Increases Investment in pHion Therapeutics to Further Develop Next Generation of mRNA VaccinesinvoX Pharma Limited has completed a second tranche of investment in pHion Therapeutics to advance its lead mRNA vaccine program, PTX_V1, into clinical trials by the first half of 2024. This transaction supports pHion's development of therapeutic vaccines for HPV-related and other cancers using its proprietary RALA delivery platform. The investment received all necessary regulatory approvals, including clearance under the U.K.’s National Security and Investment Act.Labiotech.euWatch: pHion Therapeutics talks about next-generation mRNA vaccinespHion Therapeutics, a U.K.-based vaccine developer, is developing mRNA vaccines using its RALA platform, which delivers anionic cargo into nanoparticles. Its lead product, a therapeutic HPV vaccine, has phase I/IIA trials planned for 2023, with other programs targeting ovarian, prostate, pancreatic cancers, and a next-generation COVID-19 vaccine.Silicon RepublicNew drug delivery technology could revolutionise the pharma industryPhion Therapeutics, a QUB spin-out, developed a peptide-based nanoparticle drug delivery system that can be formulated in days and targets anionic drugs to tumors. The company is in early commercialization, engaging with pharmaceutical firms, and will compete in the Invent competition in Belfast.